AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06196671
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.
Trial: NCT05660980
Drug: Once daily CAB tablet + RPV tablet
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04667507
Drug: Dexamethasone Ophthalmic implant
RxNorm normalized name: dexamethasone Drug Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone ophthalmic insert 0.4 mg for intracanalicular use
Trial: NCT06059118
Drug: DFMO
RxNorm normalized name: DFMO
DrugBank: Eflornithine (DB06243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each 119 day cycle, Days 1-7 patient will take 1000 mg by mouth (PO) twice a day (bid), and then on Day 8 - 63 patient will take 1000 mg PO bid while receiving high dose testosterone IM on Day 8 and Day 36 of cycle.
Trial: NCT06059118
Drug: testosterone cypionate
RxNorm normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 8 and Day 36 of each 119 day cycle, patient will receive high dose testosterone at 400 mg through intramuscular (IM) injection.
Trial: NCT06059118
Drug: Luteinizing hormone-releasing hormone (LHRH) analogue
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who have progressive disease after treatment with Abiraterone (Abi) will continue with androgen depravation therapy (ADT) with LHRH analogue (LHRH agonist drug (i.e. Zoladex, Trelstar, Eligard or Lupron) or LHRH antagonist drug (Degarelix or Relugolix)). Dosing instructions will vary between the different LHRH analogues. Patients should follow the dosing instructions as directed by their physician.
Trial: NCT06059118
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each 119 day cycle, Days 64-119 patient will take 160 mg by mouth (PO) once a day (qd).
Trial: NCT05346666
Drug: Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tocilizumab is an immuno-modulatory drug which act as interleukin (IL)-6 receptor inhibitor that blocks IL-6-mediated signal transduction. This drug is known to improve various diseases
Trial: NCT00002271
Drug: Alovudine
RxNorm normalized name: Alovudine
DrugBank: Alovudine (DB06198)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06109961
Drug: Oxygen Gas for Inhalation
RxNorm normalized name: oxygen Gas for Inhalation
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The active Hyperbaric Oxygen Therapy (HBOT) arm will receive 100% oxygen at 2.0-2.5 atmospheres (ATM).
Trial: NCT06650501
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.
Trial: NCT06650501
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
Trial: NCT06650501
Drug: edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
Trial: NCT06650501
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
Trial: NCT05437497
Drug: Remimazolam Injection
RxNorm normalized name: remimazolam Injection
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The experimental group was sedated with remimazolam
Trial: NCT05437497
Drug: Propofol Injection
RxNorm normalized name: propofol Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group was sedated with propofol
Trial: NCT05863416
Drug: Dexmedetomidine infusion
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative dexmedetomidine infusion
Trial: NCT06308588
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by Infusion
Trial: NCT06308588
Drug: Asciminib
RxNorm normalized name: Asciminib
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by PO
Trial: NCT05456191
Drug: Asciminib
RxNorm normalized name: Asciminib
DrugBank: Asciminib (DB12597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Asciminib 80 mg QD administered under fasting conditions.
Trial: NCT05456191
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 300 mg BID administered under fasting conditions.
Trial: NCT05464433
Drug: Tislelizumab combined with Liposomal mitoxantrone hydrochloride
RxNorm normalized name: Tislelizumab
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: liposomal mitoxantrone hydrochloride, tislelizumab Drug: Liposomal mitoxantrone hydrochloride (16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 28-day cycle.
Trial: NCT05464433
Drug: Maintenance of tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 21-day cycle
Trial: NCT06023641
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low -risk Administer IV push over 1 minute (or infusion via minibag as per institutional standards) on Day 1 of Weeks 1,8, 15 (3) doses. The maximum dose is 2 mg for all participants.~Intermediate-risk Administer IV, over 1 minute, 3 doses, weekly on day1 High-risk Administer by IV infusion over 1 minute, 3 doses, weekly on day 1,8,15
Trial: NCT06023641
Drug: Dactinomycin
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-risk Administer by slow IV push over 1-5 minutes on Day 1 of Weeks 1, (1) dose. The maximum dose is 2.5 mg for all participants.~Intermediate-risk Administer by slow IV over 1-5 minutes., 1 doses weekly on day 1 High-risk Administer by slow IV over 1-5 minutes, day1
Trial: NCT06023641
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate and High-risk Administer via slow IV push over 6-10 minutes (or infusion via minibag as per institutional standards) on Day 1 of Weeks 43-45, 47-49, 51-53, 55-57, 59-61, 63-65.
Trial: NCT05380479
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mirtazaine15 mg tablet daily for 8 weeks.
Trial: NCT05380479
Drug: Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: megestrol acetate 160 mg tablet daily for 8 weeks.
Trial: NCT06023641
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-risk Administer PO (or by NG or G tube) 5 doses, on Days 1-5 When administering with liposomal irinotecan, administer temozolomide prior to liposomal irinotecan. Preferably, administer on an empty stomach (at least 1 hour before and 2 hours after food) to improve absorption. When using temozolomide capsules, round dose to the nearest 5 mg capsule. The capsule may be opened, and contents mixed with applesauce or apple juice. A compounded oral suspension is also available. If emesis occurs within 20 minutes of taking a dose of temozolomide, then the dose may be repeated once.
Trial: NCT06023641
Drug: Filgrastim, peg-filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low, Intermediate and High-risk:~Prophylactic myeloid growth factor support (Filgrastim or Pegfilgrastim) should be used after all VAC cycles for patients on the high-risk arm. Start myeloid growth factor support (for example, filgrastim 5 mcg/kg/dose SubQ daily until the ANC is ≥ 2000/μL after the expected nadir OR pegfilgrastim 0.1 mg/kg/dose \[for patients \< 45 kg\] or 6 mg/dose \[for patients ≥ 45 kg\] SubQ x 1 dose) 24-48 hours after VAC cycles. Filgrastim may be continued without regard to VCR. Discontinue filgrastim at least 24 hours before the start of the next cycle. Prophylactic myeloid growth factor support should NOT be used after VLIT cycles or during maintenance chemotherapy.
Trial: NCT06497517
Drug: GSK5464714- Camlipixant
RxNorm normalized name: Camlipixant
DrugBank: Camlipixant (DB19217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK5464714- Camlipixant will be administered
Trial: NCT06572618
Drug: Nemtabrutinib
RxNorm normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00538811
Drug: interferon alpha-2b, ribavirin, interferon-gamma,
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00538811
Drug: interferon alpha-2b, ribavirin, amantadine
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00051662
Drug: efalizumab
RxNorm normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04578652
Drug: Metformin 850 mg oral tablet bid
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MET dose: 500 mg daily, increasing to 500 bid if tolerated after 2 weeks, then increasing again 2 weeks later to 850 mg bid (1700 mg daily).
Trial: NCT06522594
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A vey cardioselective, short-acting betablocker, with an ultra-short half life time.
Trial: NCT00268255
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05686044
Drug: Buntanetap/Posiphen
DrugBank: Posiphen (DB15317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC (vegetarian source) capsule shells
Trial: NCT06567600
Drug: Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met.
Trial: NCT06276504
Drug: Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab administration at D0, M1 and M2
Trial: NCT04197219
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg IV day 1 of each cycle every 21 days
Trial: NCT04197219
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg PO BID continuously
Trial: NCT04963985
Drug: Tafamidis Pill
RxNorm normalized name: tafamidis Pill
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral
Trial: NCT06654531
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Under a sterile technique, spinal anesthesia will be carried out using a 22-G Quincke spinal needle after skin infiltration with 2% lidocaine 3 ml a t the L3-L4 level, a midline approach in the sitting position, and then in the supine position.~Th e time of spinal injection will be considered time zero (T0). The I.V drug regimen will be started according to the group to which patients will be assigned.patients will receive intrathecal 15 mg hyperbaric bupivacaine together with 5 μg Dexmedetomidine in group 2
Trial: NCT06444191
Drug: Rilzabrutinib
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilzabrutinib tablet(s) administered orally
Trial: NCT04710888
Drug: use of basil extract gel in treatment of aphthus ulcer
DrugBank: Basil (DB10829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study aimed to evaluate the efficacy of basil extract (Ocimum basilicum) in the treatment of aphthous ulcers
Trial: NCT04986436
Drug: HS-10360
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple dose(s) of HS-10360
Trial: NCT06003348
Drug: Potassium Citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mEq Extended-release tablets for oral use
Trial: NCT04201808
Drug: Tenofovir Alafenamide 25 MG
RxNorm normalized name: tenofovir alafenamide 25 MG
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will receive Tenofovir Alafenamide, 25mg PO, to treat chronic hepatitis B and their previous suboptimal response over the study duration of 48 weeks. Patients will be followed every 12 weeks for medication adherence, medication refill, and follow up as per standard of care.
Trial: NCT05260528
Drug: Cytarabine and Idarubicin
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction 1: Cytarabine 200 mg/m2 i.v. (continuously) d1-7 + Idarubicin 12mg/m2 d1, 2, 3 i.v (60 min)~Induction 2: Cytarabine 1500 mg/m2 i.v. q12h d1-3~Consolidation: Cytarabine 1500 mg/m2 i.v. q12h d1-3
Trial: NCT05260528
Drug: CPX-315
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction 1:CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3,5~Induction 2: CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine i.v. (90 min) d1,3~Consolidation therapy:CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine i.v. (90 min) d1,3
Trial: NCT05865041
Drug: Farudodstat
RxNorm normalized name: Farudodstat
DrugBank: Farudodstat (DB16049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Farudodstat tablets administered orally
Trial: NCT06650293
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.
Trial: NCT06405633
Drug: WVE-006
RxNorm normalized name: WVE 003
DrugBank: WVE-003 (DB17870)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RNA editing oligonucelotide
Trial: NCT00669123
Drug: Chondroitin sulphate
RxNorm normalized name: Chondroitin sulphate
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chondroitin sulphate 800 mg/day
Trial: NCT04827576
Drug: Magrolimab
RxNorm normalized name: Magrolimab
DrugBank: Magrolimab (DB16225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT04827576
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously, 75 mg/m\^2 on Day 1 of each cycle
Trial: NCT01481532
Drug: Crotoxin
RxNorm normalized name: PICROTOXIN
DrugBank: Picrotoxin (DB00466)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra patient dose escalation
Trial: NCT02577094
Drug: 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG
DrugBank: Epratuzumab (DB04958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
Trial: NCT02577094
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
Trial: NCT02577094
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
Trial: NCT00002329
Drug: Celgosivir hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Celgosivir (DB06580)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06561620
Drug: Befotertinib
RxNorm normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Befotertinib is a novel, selective oral third-generation epidermal growth factor receptor tyrosine-kinase inhibitor.
Trial: NCT05533580
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The experimental group was sedated with remimazolam.
Trial: NCT05533580
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group was sedated with propofol.
Trial: NCT00989872
Drug: EDP-322
RxNorm normalized name: INDIGOFERA TINCTORIA LEAF 0.999 in 100 g TOPICAL POWDER [EDP INDIGO]
DrugBank: Indigofera tinctoria leaf (DB14314)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04888377
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant's mothers were administered 81mg of Aspirin throughout their pregnancy with the participant.
Trial: NCT05726110
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT05726110
Drug: Homoharringtonine
RxNorm normalized name: Homoharringtonine
DrugBank: Omacetaxine mepesuccinate (DB04865)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given per standard of care
Trial: NCT05726110
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given per standard of care
Trial: NCT05726110
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given per standard of care
Trial: NCT05726110
Drug: Granulocyte Colony-Stimulating Factor
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given per standard of care
Trial: NCT05726110
Drug: Aclacinomycin
RxNorm normalized name: Aclacinomycin
DrugBank: Aklavine (DB19070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given per standard of care
Trial: NCT06060327
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Giving oxytocin only, or oxytocin in addition to Tranexamic acid, Misoprostol or Carbetocin the mentioned doses and by the mention routes, then comparing the estimated blood loss in each group.
Trial: NCT05279807
Drug: Zofenopril
RxNorm normalized name: Zofenopril
DrugBank: Zofenopril (DB13166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
Trial: NCT05279807
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
Trial: NCT05003752
Drug: Goserelin 10.8 mg
RxNorm normalized name: goserelin 10.8 MG
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Androgen deprivation will be administered based on NCCN guidelines in patients with unfavorable intermediate/high risk organ-confined prostate cancer
Trial: NCT06072612
Drug: Interferon infiltration of the inoculation site
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon is a cytokine released by cells to regulate immune responses to viral infections. For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.
Trial: NCT06072612
Drug: Retifanlimab
RxNorm normalized name: Retifanlimab
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retifanlimab is a checkpoint inhibitor. A total dose of 375mg will be administered at first cycle on or about day +2 (+/-1d). In all other cycles, Retifanlimab is permitted to be administered between Day -2/-3 to Day 2±1 of the cycle based on the convenience of the patients and the clinical sites. However once the timing of the CPI is chosen for C1, it must be given on the same day thereafter throughout the trial.
Trial: NCT04739202
Drug: Atezolizumab + Ipatasertib
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Ipatasertib PO (400 mg per day continuously, starting on cycle 1 day 1). Treatment given until disease progression or unacceptable toxicity.
Trial: NCT04739202
Drug: Atezolizumab + Bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Atezolizumab IV (1200 mg on day 1 of each 21-day cycle) and Bevacizumab IV (15 mg/kg on day 1 of each 21-day cycle). Treatment given until disease progression or unacceptable toxicity.